Navigation Links
Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020
Date:10/14/2010

NEW YORK, Oct. 14 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0312710/Colorectal-Cancer---France-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020

SummaryGlobalData, the industry analysis specialist, has released its new report, "Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the French colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the French colorectal cancer therapeutics market. It analyses the treatment usage patterns in the French colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the French colorectal cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

ScopeThe Scope of the report includes:

- An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized French colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.

- Analysis of unmet need in the market and target product profile including opportunity for target product.

- Technology trends analytic framework to assess strength of pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.

- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the French Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.

- Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in France.

Reasons to buyThe report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the French colorectal cancer therapeutics market.

- Understanding treatment preferences of physicians in disease state and across treatment flow.

- Accessing market sizing, forecasts and quantified growth opportunities in the French colorectal cancer therapeutics market till 2020.

- Quantifying patient population in France to better design product pricing & launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.

- Track drug sales in the French colorectal cancer therapeutics market from 2001 to 2020

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the French Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize.

List of Figures

List of Tables

1 Colorectal Cancer: Executive Summary

1.1 The Colorectal Cancer Therapeutics Market in France was Worth $0.7 billion in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy

1.2 The Current Competition in the Colorectal Cancer Therapeutics Market in France is Weak as None of the Drugs Completely Addressed the Unmet Needs

1.3 The Colorectal Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development

1.4 High Unmet Needs Exist in the French Colorectal Cancer Therapeutics Market in terms of Efficacy and Safety

2 Disease Overview

2.1 Overview

2.2 Epidemiology

2.3 Etiology

2.4 Symptoms

2.4.1 Colon Cancer

2.4.2 Rectal Cancer

2.5 Diagnosis

2.5.1 FOBT

2.5.1.1 Sensitivity

2.5.2 Endoscopy

2.5.2.1 Sigmoidoscopy

2.5.2.2 Sensitivity

2.5.3 Optical Colonoscopy

2.5.3.1 Sensitivity

2.5.4 Virtual Colonoscopy

2.5.4.1 Sensitivity

2.5.5 Double Contrast Barium Enema (DCBE)

2.5.5.1 Sensitivity

2.6 Pathology

2.6.1 Grading

2.7 Treatment

2.7.1 Colon Cancer Treatment by Stage

2.7.2 Rectal Cancer Treatment by Stage

2.7.3 Chemotherapy Options

2.7.3.1 Adjuvant Treatment

2.7.3.2 First-line Treatment

2.7.3.3 Second-line Treatment

2.7.3.4 Third-line Treatment

2.8 Treatment Guidelines

3 Market Characterization

3.1 France

3.1.1 Market Size

3.1.1.1 Sales Value

3.1.1.2 Annual Cost of Therapy

3.1.1.3 Patient Volume

3.1.1.4 Treatment Usage Patterns

3.1.2 Drivers and Barriers

3.1.2.1 Drivers of France Colorectal Cancer Market

3.1.2.2 Restraints of France colorectal Cancer Market

3.1.3 Impact on the Market

3.1.4 Forecasts

3.1.4.1 Sales Value

3.1.4.2 Annual Cost of Therapy

3.1.4.3 Patient Volume

3.1.4.4 Treatment Usage Patterns

3.1.4.5 Future Impact

3.1.5 Drug Sales

3.1.5.1 Overview

3.1.6 Pricing & Reimbursements

3.1.6.1 Pricing of Drugs in France

3.1.6.2 Reimbursement Policy in France

3.2 Key Takeaway

4 Competitor Assessment

4.1 Strategic Competitor Assessment

4.1.1 Overview

4.1.2 Benchmarking

4.1.2.1 Clinical Endpoints Benchmarking

4.1.2.2 Safety Profile

4.1.2.3 Annual Cost of Therapy

4.1.3 Current Competitor Assessment

4.2 Launch Analysis and Sales Forecasts

4.2.1 Market Share Analysis of Drugs

4.3 Product Profiles

4.3.1 Avastin (bevacizumab)

4.3.1.1 Overview

4.3.1.2 Efficacy

4.3.1.3 Safety

4.3.1.4 Clinical Study Details

4.3.1.5 Annual Cost of Therapy

4.3.1.6 Regulatory Approvals

4.3.1.7 Life Cycle Management Activities

4.3.1.8 Product Positioning

4.3.1.9 Sales Forecast

4.3.2 Erbitux (cetuximab)

4.3.2.1 Overview

4.3.2.2 Efficacy

4.3.2.3 Safety

4.3.2.4 Clinical Study Details

4.3.2.5 Annual Cost of Therapy

4.3.2.6 Regulatory Approvals

4.3.2.7 Life Cycle Management Activities

4.3.2.8 Product Positioning

4.3.2.9 Sales Forecast

4.3.3 Xeloda (capecitabine)

4.3.3.1 Overview

4.3.3.2 Efficacy

4.3.3.3 Safety

4.3.3.4 Clinical Study Details

4.3.3.5 Regulatory Approvals

4.3.3.6 Life Cycle Management Activities

4.3.3.7 Annual Cost of Therapy

4.3.3.8 Product Positioning

4.3.3.9 Sales Forecast

4.3.4 Vectibix (panitumumab)

4.3.4.1 Overview

4.3.4.2 Efficacy

4.3.4.3 Safety

4.3.4.4 Clinical Study Details

4.3.4.5 Regulatory Approvals

4.3.4.6 Life Cycle Management Activities

4.3.4.7 Annual Cost of Therapy

4.3.4.8 Product Positioning

4.3.4.9 Sales Forecast

4.3.5 Eloxatin (oxaliplatin)

4.3.5.1 Overview

4.3.5.2 Efficacy

4.3.5.3 Safety

4.3.5.4 Clinical Study Details

4.3.5.5 Regulatory Approvals

4.3.5.6 Life Cycle Management Activities

4.3.5.7 Annual Cost of Therapy

4.3.5.8 Product Positioning

4.3.5.9 Sales Forecast

4.3.6 Camptosar (irinotecan)

4.3.6.1 Overview

4.3.6.2 Efficacy

4.3.6.3 Safety

4.3.6.4 Clinical Study Details

4.3.6.5 Annual cost of Therapy

4.3.6.6 Regulatory approvals

4.3.6.7 Life Cycle Management Activities

4.3.6.8 Sales forecast

4.3.7 Fluorouracil (5-FU)

4.3.7.1 Overview

4.3.7.2 Efficacy

4.3.7.3 Safety

4.3.7.4 Annual Cost of Therapy

4.3.8 Leucovorin (folinic acid)

4.3.8.1 Overview

4.3.8.2 Efficacy

4.3.8.3 Safety

4.3.8.4 Annual Cost of Therapy

4.4 Key Takeaway

5 Pipeline Assessment

5.1 Overview

5.2 Pipeline Analysis by Phase of Development

5.3 Pipeline by Mechanism of Action

5.4 Strategic Pipeline Assessment

5.4.1 Technology Trends Analytical Framework

5.5 Trends in Colorectal Cancer Pipeline

5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer

5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline

5.5.3 Failure of key Molecules in Phase II and Phase III Development

5.6 Partners in Development

5.6.1 Licensing Agreements by Phase of Development

5.6.1.1 Morphotek Enters Into Exclusive License Agreement with National Cancer Institute

5.6.1.2 AVEO Pharmaceuticals Enters Into Licensing Agreement with Kirin Brewery

5.6.1.3 Access Pharmaceuticals Enters Into Licensing Agreement with Jiangsu Aosaikang Pharmaceutical

5.6.1.4 Merck Enters Into Licensing Agreement with Taiho Pharmaceutical

5.6.1.5 Rexahn Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical

5.6.1.6 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology

5.6.2 Licensing Agreements by Geography

5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology

5.7 Most Promising Drugs' Profiles

5.7.1 Aflibercept

5.7.1.1 Overview

5.7.1.2 Efficacy

5.7.1.3 Safety

5.7.1.4 Clinical Study Details

5.7.1.5 Collaboration Agreements

5.7.1.6 Marketing Rights

5.7.1.7 Launch Analysis

5.7.1.8 Sales Forecast

5.7.2 Brivanib

5.7.2.1 Overview

5.7.2.2 Efficacy

5.7.2.3 Safety

5.7.2.4 Clinical trials

5.7.2.5 Collaboration Agreements

5.7.2.6 Marketing Rights

5.7.2.7 Launch Analysis

5.7.2.8 Sales Forecast

5.7.3 OncoVAX

5.7.3.1 Overview

5.7.3.2 Efficacy

5.7.3.3 Safety

5.7.3.4 Clinical Trials

5.7.3.5 Collaboration Agreements

5.7.3.6 Marketing Rights

5.7.3.7 Launch Analysis

5.7.3.8 Sales Forecast

5.7.4 TroVax

5.7.4.1 Overview

5.7.4.2 Efficacy

5.7.4.3 Safety

5.7.4.4 Clinical Study Details

5.7.4.5 Collaboration Agreements

5.7.4.6 Marketing Rights

5.7.4.7 Launch Analysis

5.7.4.8 Sales Forecast

5.7.5 KRX-0401 (Perifosine)

5.7.5.1 Overview

5.7.5.2 Efficacy

5.7.5.3 Safety

5.7.5.4 Clinical Study Details

5.7.5.5 Collaboration Agreements

5.7.5.6 Marketing Rights

5.7.5.7 Launch Analysis

5.8 Colorectal Cancer Pipeline – Preclinical Phase

5.9 Colorectal Cancer Pipeline – Phase I

5.10 Colorectal Cancer Pipeline – Phase II

5.11 Colorectal Cancer Pipeline – Phase III

5.12 Key Takeaway

6 Unmet Need

6.1 Opportunity for Target Product

6.2 Target Product Profile

6.2.1 Ideal Characteristics

6.2.2 Target Product Description

6.3 Key Takeaway

7 Strategic Assessment

7.1 Key Events Impacting the Future Market

7.2 Market Impact Analysis

7.3 Future Market Scenario

7.4 Company Analysis

7.4.1 Market Leadership

7.4.2 Future Players in the Market

7.5 Key Takeaway

8 Company Profiles

8.1 F. Hoffmann La Roche

8.1.1 Business Description

8.1.2 Financial Overview

8.1.3 SWOT Analysis

8.1.3.1 Strengths

8.1.3.2 Weakness

8.1.3.3 Opportunities

8.1.3.4 Threats

8.2 Bristol-Myers Squibb

8.2.1 Business Description

8.2.2 Financial Overview

8.2.3 SWOT Analysis

8.2.3.1 Strengths

8.2.3.2 Weakness

8.2.3.3 Opportunities

8.2.3.4 Threats

8.3 Sanofi-Aventis

8.3.1 Business Description

8.3.2 Financial Overview

8.3.3 SWOT Analysis

8.3.3.1 Strengths

8.3.3.2 Weakness

8.3.3.3 Opportunities

8.3.3.4 Threats

8.4 Debiopharm Group

8.4.1 Business Description

8.5 Merck KGaA

8.5.1 Business Description

8.5.2 Financial Overview

8.5.3 SWOT Analysis

8.5.3.1 Weakness

8.5.3.2 Opportunities

8.5.3.3 Threats

8.6 Regeneron

8.6.1 Business Description

8.6.2 Financial Overview

8.6.3 SWOT Analysis

8.6.3.1 Strengths

8.6.3.2 Weakness

8.6.3.3 Opportunities

8.6.3.4 Threats

8.7 Vaccinogen BD

8.7.1 Overview

8.7.2 SWOT Analysis

8.7.2.1 Strengths

8.7.2.2 Opportunities

8.8 Oxford BioMedica

8.8.1 Business Description

8.8.2 Financial Overview

8.8.3 SWOT Analysis

8.8.3.1 Strengths

8.8.3.2 Weakness

8.8.3.3 Opportunities

8.9 Auron Healthcare GmbH

8.9.1 Company Overview

8.10 AEterna Zentaris

8.10.1 Business Description

8.10.2 Financial Overview

8.10.3 SWOT Analysis

8.10.3.1 Strengths

8.10.3.2 Weakness

8.10.3.3 Opportunities

8.10.3.4 Threats

8.11 Keryx

8.11.1 Business Description

8.11.2 Financial Overview

8.11.3 SWOT Analysis

8.11.3.1 Strengths

8.11.3.2 Weakness

8.11.3.3 Opportunities

8.11.3.4 Threats

8.12 Abbott Laboratories

8.12.1 Business Description

8.12.2 Financial Performance

8.12.3 SWOT Analysis

8.12.3.1 Strengths

8.12.3.2 Weaknesses

8.12.3.3 Opportunities

8.12.3.4 Threats

8.13 Pfizer

8.13.1 Business Description

8.13.2 Financial Overview

8.13.3 SWOT Analysis

8.13.3.1 Strengths

8.13.3.2 Weaknesses

8.13.3.3 Opportunities

8.13.3.4 Threats

8.14 Light Sciences Oncology, Inc

8.14.1 Business Description

8.14.2 Financial Overview

8.14.3 SWOT Analysis

8.14.3.1 Strength

8.14.3.2 Weakness

8.14.3.3 Opportunities

8.14.3.4 Threats

9 Deals Analysis

9.1 Key Highlights

9.2 Key Deals' Analysis

9.2.1 Eli Lilly Acquires ImClone

9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals

9.2.3 Takeda Acquires IDM Pharma

9.2.4 Alchemia Acquires Meditech

9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron

9.2.6 BBM Holdings to Acquire YM Biosciences

9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis

9.2.8 Peptech Acquires cancer Antibodies from Scancell

9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs

9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc

9.3 Deals Analysis by Geography

9.4 Deals Analysis by Deal Size

10 Appendix

10.1 Market Definitions

10.2 Abbreviations

10.3 Research Methodology

10.3.1 Coverage

10.3.2 Secondary Research

10.3.3 Forecasting

10.3.3.1 Epidemiology-based Forecasting

Analogous Forecasting Methodology

Diseased Population

Treatment Seeking Population

Diagnosis Population

Prescription Population

Forecasting Model for Therapeutic Areas

10.3.4 Primary Research

10.3.5 Expert Panel validation

10.3.6 Contact Us

10.3.7 Disclaimer

10.3.8 Sources

Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010

Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010

Table 3: Colorectal Cancer Therapeutics Market, France, Sales Value ($), 2001–2009

Table 4: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2009

Table 5: Colorectal Cancer Therapeutics Market, France, Patient Volume ('000), 2001–2009

Table 6: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2009

Table 7: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2009–2020

Table 8: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009–2020

Table 9: Colorectal Cancer Therapeutics Market, France, Patient Volume ('000), 2009–2020

Table 10: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2009–2020

Table 11: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2010

Table 12: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2011-2020

Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010

Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010

Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010

Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010

Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010

Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010

Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010

Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010

Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010

Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010

Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010

Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010

Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010

Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010

Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010

Table 28: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010

Table 29: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010

Figure 1: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2001-2020

Figure 2: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010

Figure 3: Colorectal Cancer Therapeutics Market, France, Opportunity and Unmet Need, 2009

Figure 4: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010

Figure 5: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010

Figure 6: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2001–2009

Figure 7: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2009

Figure 8: Colorectal Cancer Therapeutics Market, France, Patient Volume, 2001–2009

Figure 9: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2009

Figure 10: Colorectal Cancer Therapeutics Market, France, Market Drivers and Restraints, 2009

Figure 11: Colorectal Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2010

Figure 12: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2009–2020

Figure 13: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009–2020

Figure 14: Colorectal Cancer Therapeutics Market, France, Patient Volume, 2009–2020

Figure 15: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2009–2020

Figure 16: Colorectal Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009–2020

Figure 17: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2020

Figure 18: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010

Figure 19: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010

Figure 20: Colorectal Cancer Therapeutics Market, France, Sales Forecast Split by Therapies, 2001-2020

Figure 21: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 2004–2010

Figure 22: Colorectal Cancer Therapeutics Market, France, Avastin, Sales Forecast ($m), 2005-2020

Figure 23: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 2004–2010

Figure 24: Colorectal Cancer Therapeutics Market, Global, Erbitux, Sales Forecast ($m), 2004-2020

Figure 25: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010

Figure 26: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010

Figure 27: Colorectal Cancer Therapeutics Market, France, Xeloda, Sales Forecast ($m), 2001-2020

Figure 28: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cycle Management Activities, 2010

Figure 29: Colorectal Cancer Therapeutics Market, France, Vectibix, Sales Forecast ($m), 2008-2020

Figure 30: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010

Figure 31: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cycle Management Activities, 2010

Figure 32: Colorectal Cancer Therapeutics Market, France, Eloxatin, Sales Forecast ($m), 2001-2020

Figure 33: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure

Figure 34: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cycle Management Activities, 2010

Figure 35: Colorectal Cancer Therapeutics Market, France, Camptosar, Sales Forecast ($m), 2001-2020

Figure 36: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure

Figure 37: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure

Figure 38: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010

Figure 39: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010

Figure 40: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010

Figure 41: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010

Figure 42: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010

Figure 43: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010

Figure 44: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010

Figure 45: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010

Figure 46: Colorectal Cancer Therapeutics Market, France, Aflibercept Sales Forecast ($m), 2011-2020

Figure 47: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010

Figure 48: Colorectal Cancer Therapeutics Market, France, Brivanib Sales Forecasts ($m), 2013-2020

Figure 49: Colorectal Cancer Therapeutics Market, France, OncoVAX Sales Forecast ($m), 2011-2020

Figure 50: Colorectal Cancer Therapeutics Market, France, TroVax Sales Forecast ($m), 2014-2020

Figure 51: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010

Figure 52: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010

Figure 53: Colorectal Cancer Therapeutics Market, Global, Opportunity and Unmet Need, 2010

Figure 54: Colorectal Cancer, Global, Key Events Impacting the Future Market

Figure 55: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010

Figure 56: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010

Figure 57: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography (%), 2010

Figure 58: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010

Figure 65: GlobalData Market Forecasting Model

To order this report:Drug and Medication Industry: Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  The global biosurgery market is ... the forecast period of 2016 to 2021. The market ... from USD 18.21 billion in 2016. The market is ... of sports related injuries and spinal problems, increasing clearance ... of effective blood loss management. In this ...
(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as ... their presence in Dallas. One of the most exciting parts for STAT is that ... Dallas and Forth Worth market. STAT takes pride in treating their employees with integrity ...
Breaking Medicine News(10 mins):